CSI Market
Sign In | Register

Serina Therapeutics Inc (SER) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access SER Annual Cash Flow →
A period-by-period view of cash flow from Serina Therapeutics Inc to Jun 30 2025 helps clarify how Jun 30 2026's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-29.12
Depreciation & amortization0.04
Amortization of Other Assets0.14
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation2.13
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.10
Gains Losses On Sales Of Assets-
Subsidiary Stockbased Compensation-
Foreign Currency Remeasurement Gain And Other-
Deconsolidation Gain Or Loss Amount-
Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest-
Noncash Lease Expense-
Fairvalue Inception Adjustment On Convertible Promissory Note-
Change In Fair Value Of Convertible Promissory Note-
Non Cash Lease Expense0.06
Gain Loss On Expiration Of Warrants-
Increase Decrease In Grant Receivables-
Increase Decrease In Operating Lease Liability-0.06
Deemed Dividend From Issuance Of Warrants-
Derecognition Of Post Merger And Incentive Warrants Liability Upon Exchange Transaction-
Exchange Of Common Stock Warrants-
Warrants Issued-
Change In Fair Value Of Liability Classified Capital Instruments-1.13
Gain Loss On Extinguishment Of Financial Commitment Assets And Contingent Warrants Net-1.62
Income taxes0.00
Gain (Loss) on Disposition of Stock in Subsidiary0.00
Increase (Decrease) in Other Receivables0.00
Increase (Decrease) in Accounts Payable-0.07
Increase (Decrease) in Accrued Liabilities0.11
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.66
Other Working Capital-0.02
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities14.78
Discontinued operations0.00
Net Cash flow from Operating Activities-11.25
Investing Activities
Capital Expenditures-0.05
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Payments To Security Deposits-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.05
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net31.25
Proceeds From Advance Of Affiliates-
Repayment Of Financing Lease Liability-
Proceeds From Line Of Credit-
Cash And Restricted Cash Acquired In Connection With Merger-
Cash And Restricted Cash Acquired In Connection With The Merger-
Proceeds From The Issuance Of Common Stock And Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities31.26
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-11.31
Total Cash Flow19.97
4 historic quarters locked

Sign in to unlock the full Serina Therapeutics Inc cash flow history.

Sign In Create Free Account

About Serina Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 13, 2026
  • Source: ser-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001708599-26-000047

Figures are derived from filed reports and may be restated. Historical data is subject to revision.